Trichodysplasia spinulosa
| Trichodysplasia spinulosa | |
|---|---|
| Synonyms | |
| Pronounce | |
| Field | Infectious disease, dermatology |
| Symptoms | |
| Complications | |
| Onset | |
| Duration | |
| Types | |
| Causes | |
| Risks | |
| Diagnosis | |
| Differential diagnosis | |
| Prevention | |
| Treatment | |
| Medication | |
| Prognosis | |
| Frequency | |
| Deaths | |
Trichodysplasia spinulosa (also known by many other names, including viral-associated trichodysplasia spinulosa, viral-associated trichodysplasia, pilomatrix dysplasia and ciclosporin-induced folliculodystrophy, although the last is a misnomer) is a rare cutaneous condition that has been described almost exclusively in immunocompromised patients, usually organ transplant recipients, on regimens of immunosuppressive drugs.<ref name="wu_2016">,
Molecular insight into the viral biology and clinical features of trichodysplasia spinulosa, British Journal of Dermatology, Vol. 174(Issue: 3), pp. 490–498, DOI: 10.1111/bjd.14239,</ref><ref name="kazem_2013">, The trichodysplasia spinulosa-associated polyomavirus: virological background and clinical implications, APMIS, Vol. 121(Issue: 8), pp. 770–782, DOI: 10.1111/apm.12092, PMID: 23593936,</ref> As of early 2016, a total of 32 cases had been reported in the medical literature.<ref name=wu_2016 /> Despite its rarity, TS is believed to be underdiagnosed, and the growing population of patients on immunosuppressive drug regimens suggests its incidence may rise.<ref name=wu_2016 /><ref name=kazem_2013 /> TS has been described as an emerging infectious disease.<ref name="nawas_2016">, Emerging infectious diseases with cutaneous manifestations, Journal of the American Academy of Dermatology, Vol. 75(Issue: 1), pp. 1–16, DOI: 10.1016/j.jaad.2016.04.033,</ref>
Symptoms
The disease is characterized by flesh-colored to erythematous (reddened) papules occurring in the central region of the face and sometimes elsewhere on the body, often accompanied by protrusive "spicules" or spines made of keratin and by alopecia of affected skin, typically the eyebrows and sometimes the eyelashes or scalp hairs. Pruritus (itching) has been described in about a third of reported cases.<ref name=wu_2016 /> Facial papules are generally 1- to 3-mm in size.<ref name="Andrews">,
Andrews' Diseases of the Skin: clinical Dermatology,
Saunders Elsevier,
2006,
ISBN 0-7216-2921-0,</ref>: 415 The condition is considered to be benign, but can be disfiguring; the spines are often prominent, and in later stages the affected facial skin thickens noticeably.<ref name=wu_2016 /><ref name=kazem_2013 />
Causes and risk factors
TS has been reported almost exclusively in immunocompromised patients, primarily organ transplant recipients on regimens of immunosuppressive drugs, and also in patients with hematolymphoid malignancies.<ref name=wu_2016 /><ref name=kazem_2013 /> As of 2016 there were no case reports in the literature describing cases of TS in patients with HIV-AIDS.<ref name=wu_2016 />
There is compelling evidence that trichodysplasia spinulosa is caused by a polyomavirus called trichodysplasia spinulosa polyomavirus (TSPyV) or Human polyomavirus 8.<ref name=wu_2016 /><ref name=kazem_2013 /><ref name="meijden_2010">,
Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient., PLoS Pathog., Vol. 6(Issue: 7), pp. e1001024, DOI: 10.1371/journal.ppat.1001024, PMID: 20686659, PMC: 2912394,</ref><ref name="kazem_2012">, Trichodysplasia spinulosa is characterized by active polyomavirus infection, Journal of Clinical Virology, Vol. 53(Issue: 3), pp. 225–230, DOI: 10.1016/j.jcv.2011.11.007, PMID: 22196870,</ref> There is evidence that exposure to the virus is common among healthy adults; estimates of seroprevalence (that is, prevalence of detectable antibodies against viral proteins) in immunocompetent adults range from 70 to 80% in different sample populations.<ref name=kazem_2013 /><ref name="meijden_2011">, Seroprevalence of trichodysplasia spinulosa-associated polyomavirus., Emerging Infectious Diseases, Vol. 17(Issue: 8), pp. 1355–63, DOI: 10.3201/eid1708.110114, PMID: 21801610, PMC: 3381547,</ref><ref name="gossai_2016">, Seroepidemiology of Human Polyomaviruses in a US Population., American Journal of Epidemiology, Vol. 183(Issue: 1), pp. 61–9, DOI: 10.1093/aje/kwv155, PMID: 26667254, PMC: 5006224,</ref> TSPyV infects the skin, but viral DNA is rarely detectable there in asymptomatic individuals even if they possess antibodies to the virus indicating exposure.<ref name=kazem_2013 /> It is not known whether TS represents new primary infection or opportunistic reactivation of a latent infection.<ref name=kazem_2013 />
Mechanism
The hyperproliferation of keratinocyte inner root sheath cells in which large aggregates of viral particles can be found suggests that TSPyV actively replicates in these cells. This is thought to underlie the clinical manifestations of TS. However, the precise mechanism is not well characterized.<ref name=kazem_2013 /> There is limited evidence implicating the large tumor antigen as responsible for inducing cellular proliferation through pathways involving phosphorylated retinoblastoma protein (pRB).<ref name=kazem_2014 />
Diagnosis

TS can be diagnosed based on clinical observations, but is usually confirmed by histopathology of a lesional biopsy or a plucked spicule. Characteristic histological findings include enlarged and abnormally organized hair follicles and hyperproliferation of inner root sheath cells containing large eosinophilic trichohyalin granules. Antibodies against major capsid protein VP1, the major component of the viral capsid, can be used to confirm the presence of viral particles in cell nuclei. Electron microscopy can also be used to detect viral particles. Quantification of viral load can be performed using quantitative PCR, as affected skin demonstrates much higher viral loads compared to unaffected skin or to asymptomatic individuals who test positive for viral DNA.<ref name=wu_2016 /><ref name=kazem_2013 />
Differential diagnosis includes other visually similar conditions affecting the hair follicles, many of which appear as drug side effects.<ref name=wu_2016 /> A proposed classification system lists TS as one of a group of cutaneous conditions with similar manifestations and distinct etiologies, collectively called the digitate keratoses.<ref name="caccetta_2012">,
Multiple minute digitate hyperkeratosis: A proposed algorithm for the digitate keratoses, Journal of the American Academy of Dermatology, Vol. 67(Issue: 1), pp. e49–e55, DOI: 10.1016/j.jaad.2010.07.023, PMID: 21050621,</ref> Although confirmed TS is rare, the condition is thought to be underdiagnosed.<ref name=wu_2016 />
Treatment
There have been too few cases of TS reported for a standard treatment to be established. In some cases, improvement in immune function has been noted to produce spontaneous improvement in TS symptoms. This pattern is consistent with the behavior of other viral diseases found in immunocompromised patients, most relevantly with the nephropathy associated in kidney transplant recipients with the polyomavirus BK virus. Antiviral drugs such as valganciclovir and cidofovir have shown benefit in treating this disorder in case reports.<ref name=wu_2016 /><ref name=kazem_2013 /><ref name="holzer_2009">,
Trichodysplasia of immunosuppression treated with oral valganciclovir, Journal of the American Academy of Dermatology, Vol. 60(Issue: 1), pp. 169–172, DOI: 10.1016/j.jaad.2008.07.051, PMID: 19103376, PMC: 2708076,</ref><ref name="wanat_2012">, Viral-Associated Trichodysplasia, Archives of Dermatology, Vol. 148(Issue: 2), pp. 219, DOI: 10.1001/archdermatol.2011.1413, PMC: 3346264,</ref>
Outcomes
TS is considered to be a benign dysplasia, although it can be disfiguring and is sometimes itchy. It is not known whether TS lesions have the potential to develop into cancer; while this outcome has never been reported, some polyomaviruses are oncogenic. The natural history of untreated TS is not known and no long-term studies of its progress have been performed. Improvement in immune function has been reported to resolve symptoms in some individual cases. Treatment with antiviral drugs has also been reported to improve symptoms, but only as long as treatment continues.<ref name=wu_2016 /><ref name=kazem_2013 />
History
TS was first described in a 1995 case report as "ciclosporin-induced folliculodystrophy", thought at the time to be an adverse effect of ciclosporin treatment.<ref name=kazem_2013 /><ref name="izakovic_1995">,
[Hair-like hyperkeratoses in patients with kidney transplants. A new cyclosporin side-effect]., Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, Vol. 46(Issue: 12), pp. 841–6, PMID: 8567267,</ref> A subsequent report in 1999, which introduced the term "trichodysplasia spinulosa", used electron microscopy to identify the presence of virus particles in affected cells consistent with what were at the time known as papovaviruses.<ref name="haycox_1999">, Trichodysplasia spinulosa--a newly described folliculocentric viral infection in an immunocompromised host., The Journal of Investigative Dermatology. Symposium Proceedings, Vol. 4(Issue: 3), pp. 268–71, DOI: 10.1038/sj.jidsp.5640227, PMID: 10674379,</ref> (The group has since been divided into the papillomavirus and polyomavirus families.) In 2010, researchers used rolling circle amplification to recover viral DNA from TS lesions and thus discovered a novel polyomavirus, trichodysplasia spinulosa polyomavirus (TSPyV). There is compelling evidence that TSPyV is the direct causative agent of TS.<ref name=wu_2016 /><ref name=kazem_2013 />
References
External links
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian